Core Insights - Eton Pharmaceuticals reported a strong financial performance for Q4 2025, achieving $21.3 million in product sales, an 83% increase year-over-year, and total revenue of $80 million for the year, more than doubling 2024's revenue [2][4][13] - The company launched three major products in 2025 and anticipates continued growth in 2026, expecting revenues to exceed $110 million with an Adjusted EBITDA margin of at least 30% [3][12] Financial Performance - Q4 2025 product sales reached $21.3 million, up from $11.6 million in Q4 2024, driven by strong sales of ALKINDI SPRINKLE and new contributions from INCRELEX, GALZIN, and KHINDIVI [4][13] - Gross profit for Q4 2025 was $13.1 million, a 102% increase from $6.5 million in the prior year [13][14] - Adjusted EBITDA for Q4 2025 was $6.2 million, representing a 195% increase compared to $2.1 million in Q4 2024 [19] Product Developments - The FDA approved DESMODA, which was launched on March 9, 2026, and is expected to generate peak sales of $30-50 million annually [5][6] - Eton acquired U.S. rights to HEMANGEOL, which will be integrated into its sales strategy and is expected to contribute positively to 2026 earnings [6] - The company is advancing clinical studies for INCRELEX label expansion, KHINDIVI reformulation, ET-700, and AMGLIDIA, indicating a robust pipeline for future growth [3][11] Market Position and Strategy - Eton's strategy includes leveraging its existing team of pediatric endocrinology specialists to enhance the commercial launch of DESMODA and expand its market presence [5] - The company has seen significant growth in GALZIN, with over 300 active patients, and aims to convert patients from non-FDA approved over-the-counter products [9] - Eton's investment in rare disease specialists and education has increased awareness and adoption of its products, positioning the company for further growth [9] Future Outlook - Eton expects to initiate key studies in 2026, including a pilot study for ET-700 and a bioequivalence study for KHINDIVI, with the goal of expanding its product indications [10][11] - The company anticipates receiving FDA feedback on its proposed study protocol by the end of March 2026, which could lead to further advancements in its clinical pipeline [8]

Core Viewpoint - Eton Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial results on March 19, 2026, with a conference call scheduled for 4:30 p.m. ET to discuss the results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering ten commercial products for rare diseases [4]. - The company has four additional product candidates in late-stage development, including Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [4].

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3] Upcoming Events - Members of Eton's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026, in Miami, Florida [1] - Interested parties can schedule a meeting by contacting their Leerink Partners institutional sales representative [2]

Core Insights - Eton Pharmaceuticals is set to participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 9:30 AM ET in New York City [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products [2] - The company's commercial rare disease products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [2] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [2]

Core Insights - Eton Pharmaceuticals is participating in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York, where its executive leadership will host 1x1 meetings [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3] - The company's commercial products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3]

Core Insights - Eton Pharmaceuticals reported a strong third quarter in 2025, with product sales increasing by 129% year-over-year, reaching $22.5 million, marking the 19th consecutive quarter of sequential growth [2][5][14]. Financial Performance - The company achieved a net revenue of $22.5 million for Q3 2025, compared to $10.3 million in the same period last year, reflecting an increase of 118% [14]. - Gross profit for the quarter was $7.9 million, up from $6.3 million in the prior year, representing a 25% increase [17]. - Adjusted EBITDA for Q3 2025 was $2.9 million, compared to $2.0 million in the prior year [22]. - The net loss for the quarter was $1.9 million, or $0.07 per diluted share, compared to a net income of $0.6 million, or $0.02 per diluted share, in the prior year [22][23]. Product Performance - The relaunch of INCRELEX significantly contributed to revenue, being the largest revenue contributor in Q3 2025, with strong adoption and awareness efforts [6][9]. - ALKINDI SPRINKLE and Carglumic Acid also showed strong year-over-year growth, supported by a dedicated sales force [11]. - The company is preparing for the launch of ET-600, with its New Drug Application accepted by the FDA and a PDUFA date set for February 25, 2026 [3][13]. Strategic Initiatives - Eton is focusing on expanding the KHINDIVI label and has received positive feedback from the FDA regarding a revised formulation aimed at younger patients [12]. - The company is pursuing harmonization of SPIGFD definitions between the U.S. and EU to increase patient access [6][8]. - Eton's cash position as of September 30, 2025, was $37.1 million, with $12.0 million generated from operations during the quarter [24]. Market Position - Eton Pharmaceuticals is positioned as an innovative company in the rare disease treatment market, with a portfolio of eight commercial products and five additional candidates in late-stage development [28].

Group 1 - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX, and Nitisinone [3] - Eton has five additional product candidates in late-stage development, such as ET-600 and ZENEO hydrocortisone autoinjector [3] Group 2 - Eton's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference from September 3-5, 2025 in Boston, MA [1] - Interested parties can schedule a meeting by contacting their Wells Fargo institutional sales representative [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has seven commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3] Upcoming Events - Eton's CEO, CFO, and Chief Business Officer will participate in two upcoming investor conferences [1] - The 25th Annual B. Riley Securities Investor Conference is scheduled for May 22, 2025, at 11:15 am ET in Marina Del Rey, California [5] - The 22nd Annual Craig-Hallum Institutional Investor Conference will take place on May 28, 2025, in Minneapolis, Minnesota [5]

Core Insights - Eton Pharmaceuticals reported exceptional first-quarter results for 2025, achieving record financial performance and launching two recently acquired products, INCRELEX and GALZIN, while advancing its development pipeline [2][4][11]. Financial Performance - Eton's first-quarter 2025 net revenues reached $17.3 million, a 117% increase from $8.0 million in the same period last year, with product sales of $14.0 million reflecting a 76% growth [11][12]. - The company reported a gross profit of $9.9 million, up 97% from $5.0 million year-over-year, driven by increased product sales [13]. - Adjusted EBITDA for the first quarter was $3.7 million, compared to $0.5 million in the prior year [18]. Product Developments - The relaunch of INCRELEX, a treatment for Severe Primary IGF-1 Deficiency, has seen a significant increase in new patients since its acquisition and relaunch [5][12]. - Eton is preparing for the anticipated launch of ET-400, targeting a $200 million market opportunity for oral hydrocortisone, with a PDUFA date set for May 28, 2025 [6][12]. - The company also relaunched GALZIN for Wilson disease and announced the development of ET-700, an extended-release form of zinc acetate [7][12]. Licensing and Partnerships - Eton out-licensed the commercial rights to INCRELEX outside the U.S. to Esteve Pharmaceuticals for up to ten years, receiving a $4.3 million upfront licensing fee [8][9]. - The licensing revenue recognized during the first quarter included $1.8 million from this out-licensing agreement [11]. Cash Position and Expenses - As of March 31, 2025, Eton had cash and cash equivalents of $17.4 million, with an operating cash flow of $2.1 million generated during the quarter [21]. - Research and Development (R&D) expenses increased to $1.2 million from $0.7 million year-over-year, primarily due to the development of ET-700 and ET-800 [15]. General and Administrative (G&A) expenses rose to $9.2 million, reflecting increased advertising and promotional costs [17].